Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
dc.contributor.author | Rodríguez Osorio, Iria | |
dc.contributor.author | Mena de Cea, Alvaro | |
dc.contributor.author | Meijide Miguez, Hector M | |
dc.contributor.author | Morano Amado, Luis | |
dc.contributor.author | Delgado Blanco, Manuel | |
dc.contributor.author | Cid Silva, Purificación | |
dc.contributor.author | Margusino Framiñán, Luis | |
dc.contributor.author | Pedreira Andrade, José Domingo | |
dc.contributor.author | Castro Iglesias, Angeles | |
dc.date.accessioned | 2022-01-25T12:18:22Z | |
dc.date.available | 2022-01-25T12:18:22Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1932-6203 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546209/pdf/pone.0217052.pdf | es |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/31158237 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/15935 | |
dc.description.abstract | BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged >/=65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC). OBJECTIVE: To compare the incidence of liver-related events and mortality between patients aged >/=65 and <65 years. METHODS: Prospective study comparing patients aged >/=65 and <65 years treated with DAAs. The incidence of liver-related events and mortality, and HCC was compared between age groups. RESULTS: Five hundred patients (120 aged >/=65 and 380 aged <65 years) were included. The incidence of liver-related events was 2.62 per 100 patient-years (py) in older and 1.41/100 py in younger patients. All-cause mortality was 3.89 and 1.27/100 py in older and younger patients, respectively. The respective liver-related mortality rates were 1.12 and 0.31/100 py. In patients with cirrhosis (stage F4), all-cause mortality (P = 0.283) and liver-related mortality (P = 0.254) did not differ between groups. All five liver-related deaths were related to multifocal HCC. The incidence of HCC was 1.91 and 1.43 per 100 py in the older and younger groups, respectively (P = 0.747). The diagnosis of HCC was 8 months after the end of treatment. CONCLUSIONS: The incidence of liver-related events and liver-related mortality was low in older people treated with DAAs and was similar to that in younger patients. The extra mortality in people aged >/=65 years treated with DAAs seems to be secondary to non-liver-related causes. These results support the utilization of DAAs in patients aged >/=65 years. | en |
dc.language.iso | eng | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Hepatitis C | * |
dc.subject.mesh | Carcinoma | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Carcinogenesis | * |
dc.subject.mesh | Liver | * |
dc.subject.mesh | Liver Neoplasms | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Antiviral Agents | * |
dc.title | Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals | es |
dc.type | Artigo | es |
dc.identifier.doi | 10.1371/journal.pone.0217052 | |
dc.identifier.pmid | 31158237 | |
dc.identifier.sophos | 32416 | |
dc.issue.number | 6 | es |
dc.journal.title | PLoS One | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Dixestivo | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Farmacia | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña::Medicina Interna | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Medicina Interna | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC) | es |
dc.rights.accessRights | openAccess | es |
dc.subject.decs | carcinoma | * |
dc.subject.decs | anciano | * |
dc.subject.decs | antivíricos | * |
dc.subject.decs | hígado | * |
dc.subject.decs | hepatitis C | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | humanos | * |
dc.subject.decs | neoplasias hepáticas | * |
dc.subject.decs | carcinogénesis | * |
dc.subject.keyword | CHUAC | es |
dc.subject.keyword | CHUVI | es |
dc.subject.keyword | INIBIC | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 14 | es |